vigamox 5 mg/ml øjendråber, opløsning
novartis healthcare a/s - moxifloxacinhydrochlorid - øjendråber, opløsning - 5 mg/ml
nocutil 0,1 mg tabletter
gebro pharma gmbh - desmopressinacetattrihydrat - tabletter - 0,1 mg
nocutil 0,2 mg tabletter
gebro pharma gmbh - desmopressinacetattrihydrat - tabletter - 0,2 mg
rambo vandopløseligt koncentrat
klarsø a/s - glyphosat - vandopløseligt koncentrat - 120 g/l glyphosat
rambo spray vandopløseligt koncentrat
klarsø a/s - glyphosat - vandopløseligt koncentrat - 7 g/l glyphosat
duzallo
grunenthal gmbh - allopurinol, lesinurad - gigt - antigout præparater - duzallo er indiceret hos voksne til behandling af hyperuricaemia i gigt patienter, der ikke har opnået målet serum-urinsyre med en passende dosis af allopurinol alene.
zurampic
grünenthal gmbh - lesinurad - hyperurikæmi - antigout præparater - zurampic, er i kombination med en xanthin oxidase inhibitor, indiceret hos voksne til adjuverende behandling af hyperurikæmi i gigt patienter (med eller uden tophi), der ikke har nået målet serum urinsyre niveauer med en passende dosis af en xanthin oxidase inhibitor alene.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leukæmi, lymfocytisk, kronisk, b-celle - antineoplastiske midler - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.